Allentown Residents Can Find Affordable Dental Implants in Easton

ADS logo for dentists in Easton

ADS and its team of Easton dentists are offering Allentown dental implants and dentures at affordable prices.

Affordable Dental Solutions is only minutes away from Allentown, PA.

Dental implants don’t only change a patient’s smile. They change their life.”

— Dr. Michelle Bernreuther

EASTON, PA, UNITED STATES, August 14, 2018 /EINPresswire.com/ — The Easton dentists at Affordable Dental Solutions (ADS) are welcoming new patients from nearby Allentown. Residents can escape the high cost of dentists in Allentown by visiting our ADS location in Easton where dental implants are only $2,000.

The low price of dental implants in Easton includes both the abutment and final restoration. Dental implants are among the most popular solutions for missing teeth because of their natural look and feel.

“Dental implants don’t only change a patient’s smile. They change their life,” says Dr. Michelle Bernreuther, dentist in Easton.

ADS also offers affordable dentures in Easton. Full dentures in Easton cost only $650/arch and partial dentures cost $750/arch. Implant-retained dentures are also available for $2,999 when two dental implants are added to a patient’s full lower dentures.

To learn more about the dentures and dental implants available to Allentown residents and to schedule an appointment with the Easton dentists at ADS, visit http://www.eastonimplants.com/appointment.html.

About Affordable Dental Solutions: Based in Eastern Pennsylvania, Affordable Dental Solutions is a provider of full dentistry services. For nearly a decade, Affordable Dental Solutions has offered patients procedures such as dental implants, crowns, and dentures at rates much lower than area competitors by utilizing state-of-the-art equipment and by negotiating discounts with implant manufacturing companies. Learn more at https://www.affordabledentalsolutions.com/.

Jamie Jaskolka
Affordable Dental Solutions
(484) 948-2900
email us here

About Affordable Dental Solutions


Source: EIN Presswire

Dr. Kam Habibi Reveals How to Become a Dental Hygienist

Becoming a dental hygienist takes hard work and dedication but it is also extremely rewarding.

SARASOTA, FL, UNITED STATES, August 14, 2018 /EINPresswire.com/ — Dentistry is a niche medical market where many hygienists have found a home. This is a prosperous field with a lot of possibility for advancement. Plus, the hours are usually Monday through Friday, nine to five.

These incentives pale to the pay scale of the job, however, which make the occupation even more inviting. According to Dr. Kam Habibi, dental hygienists make an average of $72,901 per year. With that in mind, Dr. Kam Habibi is keen to reveal how a person interested in dentistry can become a dental hygienist.

The Scope of the Job

A dental hygienist has many different tasks. First, the hygienist escorts the patients to their dental room. This might sound menial, but it is extremely important. People are often fearful of going to the dentist, despite medical advancements. Therefore, being friendly and reassuring helps put the patients at ease. Next, the hygienist is tasked with cleaning the patient’s teeth and taking x-rays. They are also the person to decipher if the patient is having any trouble with their teeth. Once the dentist comes in, the dental hygienists assist the doctor with procedures and figuring out the cause of discomfort.

Get Certified

To become a dental hygienist, a person must first achieve at least an Associate Degree in Dental Hygiene. Aspiring hygienists can decide to attend a traditional college or dental school. Either way, after at least two years, applicants are qualified to take their licensure examinations. This is the next step to becoming a dental hygienist.

However, if a dental hygienist is interested in teaching, research, or clinical practice, a bachelor’s degree is required. This usually takes an additional two years. Yet, receiving this extra education will allow dental hygienists a plethora of opportunities. It might even help the applicant stand out among others when it is time to search for a job. Although to land a traditional dental hygienist job, only an associate degree is required.

Obtain License

The Commission on Dental Accreditation (CODA) is the only accredited institution for obtaining a dental hygienist license. However, there are programs that CODA offers available throughout the country. Therefore, finding a place to obtain a license should not be a difficult feat. The only caveat is that each state requires a license. Thus, a dental hygienist can only practice in the state that they are licensed in. While that makes sense, it is a fact that aspiring dental hygienists should be aware of.

Get to Work

Once a dental hygienist has received their CODA approved the license, though, they are free to get a job within the state. Throughout the process, it is a good idea to garner as many resources as possible, to simplify the job search. After all, if a person knows the applicant from the certification process, they are more likely to hire them.

To close, Dr. Kam Habibi is highly supportive of people wishing to enter the dental hygienist field. This is a well-paying medical support job that can lead the hygienist comfortably into retirement. Once dental hygienists find the right practice, there is little reason for them to work anywhere else. Therefore, many dental hygienists are contented in their position, but they always can learn more and advance.

Eric Ash
Web Presence, LLC
941-266-8620
email us here


Source: EIN Presswire

Mary Beth McGuinn LCSW to be Featured on CUTV News Radio

RAMSEY, NEW JERSEY, UNITED STATES, August 14, 2018 /EINPresswire.com/ — Mary Beth McGuinn, LCSW is a seasoned therapist and a go-to person when working with clients going through transitions in their lives. Worry, depression and anxiety are often a consequence of not feeling confident when changes arise. Feeling disconnected from life, people often feel powerless to make the right decisions. McGuinn, LCSW uses her expertise from 20 years in a therapeutic practice to guide clients to be able to manage their lives, have less anxiety and be more confident. Mastering techniques to take things down a notch, clients leave sessions with less tension and more hope for resolving what is on their minds.

“My focus in therapy and coaching with clients is to help them be the best they can be and shift from being a victim to being a victor,” says McGuinn.

“It is not about looking at someone and saying what is wrong with this person,” says McGuinn. “I look at clients I work with and wonder, ‘What has kept them stuck in life? I explore this with my clients in therapy and help them get clear on where they are going. I am a life-long learner, always learning new information to bring to my clients from Neuroscience to Energy Psychology.”

Pairing Energy Psychology, EFT Tapping with traditional therapy and coaching, McGuinn’s integrative approach allows clients to not only clear negative thoughts but help ease tensions in your body. Her eclectic approach draws from Psychoanalysis, Cognitive Behavioral Therapy and Grief Recovery Work.

In addition to receiving Advance Standing at Adelphi University, she has done post graduate work at the New Jersey Institute for Training in Psychoanalysis and a certification from the Grief Recovery Institute. She co-authored with Jack Canfield a recent bestselling book titled the Road to Success Volume 1.

She works in Ramsey, New Jersey and can be found on the therapist directory of PsychologyToday.com.

CUTV News Radio will feature Mary Beth McGuinn in an interview with Jim Masters on July 25th at 11am EDT.

Listen to the show on BlogTalkRadio.

If you have a question for our guest, call (347) 996-3389

Lou Ceparano
CUTV News
(631) 850-3314
email us here


Source: EIN Presswire

California Court Rules Against Monsanto in RoundUp Case

Mike Brandner Injury Attorneys

Mike Brandner Injury Attorneys is now accepting claims for review to represent you if you’ve been a victim of Monsanto and RoundUp.

Too often, massive companies tend to operate like their actions do not have consequences. Anyone who has been hurt at the hands of this product should receive their due justice and compensation.”

— Mike Brandner

NEW ORLEANS, LOUISIANA, US, August 14, 2018 /EINPresswire.com/ — On Friday, August 10, 2018, a California jury ruled against agriculture business giant Monsanto and their weed-killer product RoundUp. They decided that the product led to the development of terminal cancer in Dewayne Johnson, a former school groundskeeper that used RoundUp as a regular part of his job. As a result, Johnson was awarded $39 million in compensatory and $250 million for punitive damages. Mike Brandner Injury Attorneys is now accepting claims for review to represent you if you’ve been a victim of Monsanto and RoundUp.

A Huge Wake Up Call
For years, users of RoundUp have claimed that ingredients present in the product, especially glyphosate, has led to them developing cancer, specifically non-Hodgkin's lymphoma. Monsanto has feverently denied these claims. However, a California court disagreed with Monsanto and decided that the company should have placed a warning label on the product to warn potential users of the health risks. According to Robert F. Kennedy Jr., "This jury found Monsanto acted with malice and oppression because they knew what they were doing was wrong and doing it with reckless disregard for human life. This should send a strong message to the boardroom of Monsanto."

This is the first lawsuit concerning RoundUp that has made it to trial. Many lawyers believe this case has established a massive precedent for the remaining thousands of cases still pending against Monsanto and RoundUp. According to CNN, more than 800 patients were in the process of suing Monsanto last year, claiming Roundup caused them to develop cancer.

Still, Monsanto stands by the safety RoundUp and is not going down without a fight. Monsanto Vice President Scott Partridge said, “We will appeal this decision and continue to vigorously defend this product, which has a 40-year history of safe use and continues to be a vital, effective and safe tool for farmers and others."

If you or a loved one developed non-Hodgkin’s lymphoma, or other cancers, after using RoundUp, you should not have to go to trial alone. Now is the time to discuss your case and make a plan for your pursuit of the compensation you so rightfully deserve.

Personal injury attorney Mike Brandner says, “Too often, massive companies tend to operate like their actions do not have consequences. My team and I want to assure that anyone who has been hurt or suffered loss at the hands of this product will receive their due justice and compensation. We want aid your fight against this giant corporation.”

More About Mike Brandner Injury Attorneys
Mike Brandner Injury Attorneys has successfully represented victims from a variety of backgrounds with lawsuits against large insurance companies, Fortune 500 companies, large corporations, condominium associations, labor unions, and more involving injuries related to traffic accidents, defective products, workplace accidents, maritime accidents, railroad accidents (FELA), and other accidents. Find out more about Mike Brander and his team of Louisiana personal injury attorneys online at branderlawfirm.com or by calling (504) 345-1111. You can also interact with the law firm by connecting with them on Twitter and Facebook.

Mike Brandner
Mike Brandner Injury Attorneys
(504) 345-1111
email us here


Source: EIN Presswire

The SafeCare Group Announces the Addition of New Board Member

Ray Montgomery

SafeCareSoft®

The SafeCare Group®

Veteran healthcare leader Ray Montgomery joins The SafeCare Group board

Ray is a pioneer in the healthcare industry and we are delighted to welcome him to The SafeCare Group board”

— Yisrael Safeek, MD, MBA, The SafeCare Group President and CEO

LEXINGTON, KENTUCKY, USA, August 14, 2018 /EINPresswire.com/ — The SafeCare Group® today announced the appointment of veteran healthcare leader and retired Unity Health President and CEO Ray Montgomery II, MBA, FACHE to its Board of Advisors.

“Ray is a pioneer in the healthcare industry and we are delighted to welcome him to The SafeCare Group board,” said Yisrael Safeek, MD, MBA, The SafeCare Group President and CEO. “He is a nationally recognized healthcare leader, and we believe his strong experience, especially on national hospital boards, will be extremely valuable as The SafeCare Group continues to grow and achieve our potential as a healthcare software company.”

About Ray Montgomery
Mr. Montgomery served on the board of the American Hospital Association and served as chairman of the Regional Policy Board 7 from 2010-2012, and on the Arkansas Hospital Association Board for more than 17 years. He is currently the AHA representative on the Arkansas Foundation for Medical Care and the Arkansas Center for Health Improvement boards of directors. For close to 30 years, Mr. Montgomery led his healthcare system through extensive facility improvements, facilitated a major rebranding, which included a name change to Unity Health, the acquisition of hospitals and the building of a Cancer Center of Excellence. During his leadership, Unity Health earned the honor of the Arkansas Governor’s Quality Award twice, and he is a past recipient of the A. Allen Weintraub Memorial Award, the highest honor given by the Arkansas Hospital Association for a hospital executive. In 2014, the Arkansas Hospital Association named him its Grassroots Champion.

About The SafeCare Group®
The SafeCare Group was founded in 2010 and its motto is “Innovating, Disrupting, Transforming” healthcare. SafeCareSoft® SaaS solutions enable hospitals to take advantage of disruptive healthcare software known as Softwaring Healthcare Excellence® that optimize hospital reimbursement and accreditation. Since 2012, SafeCare Analytics® have been helping hospitals excel with physician privileging software for Joint Commission OPPE, and hospital software for better readmissions, complications, infections, and value. Since 2013, 100 SafeCare Hospitals® listings have been Recognizing Healthcare Excellence® of 100 US hospitals that excelled with low infections, readmissions, complications, high patient satisfaction, and high value. Since 2015, SafeCare® magazine has been delivering information on the people, ideas and novel technologies affecting access, cost, and quality of healthcare across the globe. For more information about The SafeCare Group’s board, visit
https://www.safecaregroup.com/about.html

Sarju Bharucha, JD
SafeCare Magazine
800-700-9481
email us here

10 Reasons Your Hospital Needs SafeCareSoft®


Source: EIN Presswire

Mental Health Watchdog on a Crusade to Protect Children from Illegal Baker Acts

Who Speaks for the Child?

The headquarters for CCHR Florida are located in downtown Clearwater

The headquarters for CCHR Florida are located in downtown Clearwater

CCHR Florida

32,763 involuntary examinations were initiated on children during 2016-2017 according to a report recently released by the Baker Act Reporting Center.

The criteria for involuntary examination clearly allows for a parent or legal guardian to be given the opportunity to care for their child yet this fundamental right is being stripped away.”

— Diane Stein, President of CCHR Florida

CLEARWATER, FLORIDA, UNITED STATES, August 14, 2018 /EINPresswire.com/ — The Citizens Commission on Human Rights (CCHR), a non-profit mental health watchdog dedicated to the protection of children, has reached over 184,000 families in a campaign to stop the illegal Baker Acting of children in Florida.

The Florida chapter of CCHR is on a crusade to prevent unjust involuntary psychiatric examination of children without parental knowledge. Educating families on their rights at hundreds of local events, CCHR also hosts free seminars delivered by a local attorney on the mental health law at their headquarters located in downtown Clearwater.

The mental health law in Florida, commonly known as the Baker Act, allows for the initiation of an involuntary psychiatric examination of anyone no matter their age and this includes children as young as two years of age.

“We receive calls on a weekly basis from the parents of children that have been Baker Acted without their knowledge,” said Diane Stein, President of CCHR Florida. “This is a violation of the rights of the child and the parent.”

Seen as a statewide crisis, 32,763 involuntary examinations were initiated on children during 2016-2017 according to a report recently released by the Baker Act Reporting Center. [1]

Taking action to stop this abuse, CCHR began educating families on their rights in 2016 and has reached over 184,000 families with information on the Baker Act as well as providing them with a form designed to help prevent unjust involuntary examination. The form, created by attorneys, makes it clear that the parent is not relinquishing their parental rights and also clearly states that the parent is not giving permission for a psychiatric examination of their child for any purpose. This statement is based on Chapter 394.463 of the Florida Statutes, which reads as follows: "Without care or treatment, the person is likely to suffer from neglect or refuse to care for himself or herself; such neglect or refusal poses a real and present threat of substantial harm to his or her well-being; and it is not apparent that such harm may be avoided through the help of willing family members or friends or the provision of other services."

“The criteria for involuntary examination clearly allows for a parent or legal guardian to be given the opportunity to care for their child yet this fundamental right is being stripped away,” said Stein.

Concerned parents are encouraged to contact CCHR to learn more about their rights under the law at 800-782-2878 and to sign a petition asking Florida lawmakers to amend the Baker Act.

About CCHR: Initially established by the Church of Scientology and renowned psychiatrist Dr. Thomas Szasz in 1969, CCHR’s mission is to eradicate abuses committed under the guise of mental health and enact patient and consumer protections. L. Ron Hubbard, founder of Scientology, first brought psychiatric imprisonment to wide public notice: “Thousands and thousands are seized without process of law, every week, over the ‘free world’ tortured, castrated, killed. All in the name of ‘mental health,’” he wrote in March 1969. For more information visit www.cchrflorida.org.

Source:
[1] Fiscal Year 2016/2017 Annual Report http://www.dcf.state.fl.us/programs/samh/publications/The%20Baker%20Act%20-%20FL%20MH%20Act%20-%20FY%2016-17%20Annual%20Report%20-%20Released%20June%202018.pdf

Diane Stein
Citizens Commission on Human Rights of Florida
(727) 422-8820
email us here

“The Baker Act”


Source: EIN Presswire

HealthTech Healx raise $10m to accelerate drug discovery, prior to speaking at Orphan Drugs and Rare Diseases Conference

Orphan Drugs and Rare Diseases 2018

Orphan Drugs and Rare Diseases 2018

HealthTech Healx, who raised $10m to advance drug discovery & treatments for rare diseases, set to speak at 8th Annual Orphan Drugs and Rare Diseases Conference

LONDON, WATERLOO, UNITED KINGDOM, August 14, 2018 /EINPresswire.com/ — Healx, a HealthTech company based in Cambridge who are also set to speak at this year’s Orphan Drugs and Rare Diseases conference in October in London, have announced a $10m (£7.6m) Series A funding round. The company's primary focuses include using AI to develop treatments for rare diseases, cutting down the time it takes to get drugs into market, finding new uses for existing drugs and their application in combination therapies.

Patients with rare diseases cannot continue to be overlooked because of costly therapies and have the same rights to treatment as any other patient. Dr David Brown, one of the company's founders, stated “The traditional drug discovery process takes 10 to 15 years at a cost of $2 billion per new drug and with a failure rate of 95% – it’s broken, it’s slow, it’s high failure, and it’s not economic for rare diseases. Healx is showing that we can massively transform the rate of discovery of new medicines, reducing timelines and costs.”*

The orphan drugs market has seen a huge growth in interest from pharmaceutical companies and biotechs, as a growing need for effective, long-term treatment for rare disease patients becomes a priority. Companies like Healx are paving the way to success by repurposing existing drugs, meaning fewer complex trials, less expenditure, and a quicker timeline.

This year's 8th annual Orphan Drugs and Rare Diseases conference, taking place 17 – 18 October in London, will be hosting Healx's Head of Business Development Michale Bouskila-Chubb, who is set to present on "Accelerating drug discovery for rare diseases using AI: The Healx Model".

Michale will be focusing on fragile X case study: the case for AI-driven drug repurposing vs conventional drug repurposing, setting up an online tool to share data: how patient groups can accelerate data access and data quality for their rare diseases, and translating repurposed drugs to pharma: how we can build viable commercial cases for the pharmaceutical industry.

At this year’s two-day conference, delegates will be able to hear from Healx and many more industry leaders, including Sobi, MHR AstraZeneca, Genetic Alliance and more.

2018 Conference Highlights:

• Discuss the pricing and reimbursement of orphan drugs
• Understand the challenges of patient recruitment and patient-centric research
• Hear the MHRA’s perspective on benefit-risk assessment in rare diseases
• Explore the clinical development of orphan drugs for rare diseases
• Gain insight into potential synergies between regulators, non-profits and pharmaceutical companies

The conference’s last early bird saving of £200 expires on August 31st and delegates are urged to book soon to join an unrivalled gathering of international expert speakers and industry professionals for 5+ hours of pure networking. Visit the website to download the full speaker interviews, see the agenda and keep up to date with the latest developments at http://www.orphandrugs.co.uk/einpr

*uktech.news

—- END —
About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Maria Mandic
SMi Group
email us here
+44 (0) 207 827 6000


Source: EIN Presswire

SMi’s Exclusive Interview with Mark Albrecht, Project Officer, HHS/ASPR/BARDA

Interview: Mark Albrecht

NEW JERSEY , ISELIN, USA, August 13, 2018 /EINPresswire.com/ — SMi Reports: An exclusive interview with Biomedical Advanced Research and Development Authority (BARDA) acting Chief Mark Albrecht has been released in the run-up to the 3rd annual Superbugs & Superdrugs USA Conference taking place in Iselin, New Jersey on November 12 – 13, 2018.

Mark provided us with some insightful content about his role in the field, his view on challenges within the field and his vision on the future of the development of novel anti-infectives. His presentation will focus on ‘Supporting Antibacterial Research and Development’, how BARDA partners with industry to stimulate innovation in AMR R&D and how CARB-X is refilling the preclinical AMR product pipeline.

He works closely with product sponsors to advance the development of their antibacterial candidates, towards consideration for regulatory approval for both public health and biodefense indications, coordinating efforts to advance the development of bio-defence medical countermeasures and ensure that Government agency portfolios are properly aligned.

By attending our 3rd annual Superbugs & Superdrugs USA event, not only would you benefit from the knowledge delivered through a range of thought-provoking presentations, by experts at the forefront of the field; but you would also receive the opportunity to interact with and exchange ideas with decision makers from all of the different facets of the industry – from research to commercial providers and regulatory bodies.

–SNAPSHOT OF INTERVIEW–

Q. What do you see as the greatest hurdle to developing novel and effective anti-infectives?
A. There are a variety of challenges affecting the antibacterial development industry including optimal pipeline composition to withstand attrition and the development of resistance, and clarity on the development/regulatory path for a single pathogen anti-infective; however, there has been far greater discussion regarding the lower commercial returns antibiotics generate compared to other therapeutic areas such as cancer or heart disease. Given that antibiotic development is financially challenging with an uncertain return on investment (ROI) it is clear that both push mechanisms (CARB-X, GARD-P, NIAID, Wellcome Trust, BARDA, etc.) and pull incentives are necessary. In particular, pull incentives will ensure companies have a predictable ROI for developing these drugs that society requires, but undervalues. Dozens of publications have described a variety of incentive structures, any of which would involve tradeoffs for all parties, including sponsors, non-profit organizations, and payers, therefore, there is work to be done to establish a consensus recommendation for policymakers.

Q. What do you hope to gain from this meeting?
A. I am looking forward to the opportunity to meet all the attendees and speak with them about their products, challenges and the opportunities that CARB-X and BARDA offer.
At this year’s two-day conference, delegates will be able to hear from HHS/ASPR/BARDA and many more industry leaders, including Scynexis, Janssen, Octagon Therapeutics, Astellas and more.

– Download the full interview online –

2018 Conference Highlights:
* Gain Insight into Diagnostic Technologies being used in the field and the futuristic developments
* Learn about pathogen focused drug development
* Hear from the main regulatory bodies to advise on guidelines surrounding funding and development
* Explore new companies on developing novel approaches to circumvent antibacterial resistance
* Discover new approaches of anti-fungal development
* Case-study examples of rapid diagnostic methods currently being used in the field
* Network with key industry leaders and benefit from though provoking discussions

The conference’s last early bird saving of US$100 expires on September 28th and delegates are urged to book soon to join an unrivalled gathering of international expert speakers and industry professionals for 5+ hours of pure networking. Visit the website to download the full speaker interviews, see the agenda and keep up to date with the latest developments at www.superbugs-usa.com/pr7

SMi presents the 3rd annual industry leading conference:
Superbugs & Superdrugs USA
Date: 12th – 13th November 2018
Location: Renaissance Woodbridge Hotel, Iselin, New Jersey
Website: www.superbugs-usa.com/pr7

Contact Information:
For sponsorship bookings, contact Alia Malick Director on +44 (0)20 7827 6168 or email amalick@smi-online.co.uk
Book your place online at www.superbugs-usa.com/pr7

Follow us on: Twitter – @SMIpharm & #smibugs | LinkedIn – @SMi Pharma

—- ENDS —-

About SMi Group
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Jinna Sidhu
SMi Group
+44 (0) 207 827 6088
email us here


Source: EIN Presswire

Pease & Associates CPAs is recognized in the TOP 300 Accounting Firms, moving up from the 284 ranking to 267 this year

As one of 42,000 CPA firms in the country, we are honored to be recognized as one of the top 300 in the US. It is because of our dedicated people, along with our loyal base of entrepreneurial clients.”

— Joseph V. Pease, Jr., Founder, CPA Pease & Associates, CPAs

CLEVELAND, OHIO, UNITED STATES OF AMERICA, August 13, 2018 /EINPresswire.com/ — IPA Releases Ranking of Top 300 Firms – Transformative change is moving across the profession like a reverse ripple on a pond – embraced first by nimble, innovative firms on the fringes of the mainstream, with the ripples now spreading inward to the core of the largest firms in the country. Pease & Associates CPAs has been ranked in the top 300 for the past 2 years, last year's ranking was 284, this year's 267.

About Pease & Associates, CPAs:
Pease & Associates, CPAs has been proudly serving the Cleveland area as a CPA firm for more than 15 years. As we’ve grown to have more than 80 employees, we still provide the same exceptional quality of service and customer support that has separated us from the start. We seek to exceed your expectations, while providing honest, dependable tax, audit, and estate planning services. When you don’t know where to turn to find a CPA, you want to choose a reputable company, one you can trust, and one with the firsthand experience you or your business needs.

As opposed to many CPAs, our firm has a more streamlined focus, enabling us to offer you truly specialized, expert assistance. Our CPA company handles tax services, auditing and assurance, business consulting, and estate planning, with a proven track record of expertise.

We have three local offices in Cleveland, Akron and Beachwood, Ohio. Call us at 216.348.9600 to learn more about how we can help, and why you can always be confident in choosing Pease & Associates, CPAs as your CPA firm.

About INSIDE Public Accounting:
The Platt Group, based in Indianapolis, was founded in 2006 by husband and wife team Mike and Kelly Platt, who purchased INSIDE Public Accounting (IPA) from founder Martha Hudson-Sawyer after a successful 20-year run. This highly regarded independent publication was formerly known as Bowman’s Accounting Report. IPA publishes two award-winning publications: the IPA newsletter and the annual IPA National Benchmarking Report, along with in-depth reports focused on IT, HR and firm administration.

David Pease, MBA | Marketing Director
Pease & Associates, CPAs
216.472.4455
email us here


Source: EIN Presswire

The critical and chronic care products for North America are expected to grow at a CAGR of 6.9%

Global Critical and Chronic Care Products Market anticipated to grow at a CAGR of 5.23% to reach value of $15064.02 million by 2023

HYDERABAD, TELANGANA, INDIA, August 13, 2018 /EINPresswire.com/ — In the Report “Critical and Chronic Care Products Market: By Treatment (Surgical, Paediatric, Psychiatric, Others); By Device (Anaesthesia Airways, Infusion Systems, Ventilators, Others); By Temperature Management, Vascular Access, Patient Care; By End-User (Hospitals, Clinics, Others); By Geography – (2018-2023)” published by IndustryARC, the market is driven by the rising number of hospitals and clinics, which cater to the patients suffering from both chronic and critical illness.

Asia-Pacific dominating with major share in the Critical and Chronic Care Products Market

Geographically, North America accounted for the maximum share of 45% in 2014 owing to the high standard of the hospitals and devices used. The market was valued at $4977 million in 2017. The critical and chronic care products for North America are expected to grow at a CAGR of 6.9%, to reach a value of $6536.27 million by 2023.

Europe is the second leading market in the industry with a value of $3131 million by 2017. The market is projected to grow at a CAGR of 4.0%, and to reach a value of $3930.5 million by 2023. Asia-Pacific is projected to grow at the fastest pace of a CAGR 6.9%, to reach a value of $3473.86 million by 2023. The critical and chronic care solution market has been growing tremendously over the past decade with new and improved products spearheading the market.

Selected Types of foods Analysis done in the full Report:

Infusion systems account for the largest share in revenue by type of device. The infusion systems are used to accurately deliver infusions. They are used in ICU rooms, general wards and care centers. Infusion systems market accounted for revenue of $3836 million in 2017. The market for infusion systems is expected to grow at a CAGR of 3.8% and to reach a value of $4780.13 million by 2023. Anesthesia airway is the second leading market that accounted to $2247 million in 2017. The market is expected to grow at a CAGR of 4.5% and to reach a value of $2908.19 million by 2023, followed by patient monitoring leading the market next. Recent findings state that drainage systems and pressure monitoring is expected to grow at the highest CAGR of 8.5% and 8.1% respectively. Drainage systems and Pressure monitoring is expected to reach a value of $2821.36 million and $436.33 million by 2023 respectively. Ventilators type is expected to reach an average rate of 5.2%, to reach a value of $1323.10 million by 2023.

To access / purchase the full report browse the link below:
https://industryarc.com/Report/6358/Critical-and-Chronic-Care-Market-Research-Report.html

Excerpts on Market Growth Factors

Development in home healthcare segment will mainly be driven by technological advances, enabling improvement of affordable health monitoring devices. The rise in the demand for home health monitoring device will propel the market for chronic care products.
3-D printing will help in customizing interventional treatments as per individual patient needs, as clinicians will be able to manufacture devices to specific sizes and shapes. This launch of technology will propel the critical and chronic care products market.
The number of deaths due to chronic diseases is very high in emerging countries such as India, China and Brazil. To combat the situation health authorities are bound to invest in chronic health monitoring and treatment devices which will propel the market for Chronic care products.
Competitors are working on the development in home healthcare segment, which will mainly be driven by technological advances enabling improvement of affordable health monitoring devices. The rise in demand for home health monitoring device will propel the market for chronic care products.

Talk to one of our sales representative about the full report by providing your details in the link below:
https://industryarc.com/support.php?id=6358

Key players of the Critical and Chronic Care Products Market

Key players in critical and chronic care market are GE Healthcare (U.S.), Philips Healthcare (The Netherlands, Medtronic Plc. (U.S.), and Smiths Medical (U.K.). The companies are making new entry with innovative products, in the fiscal year 2018. Some of the major launch of critical and chronic care products of key players are Philips Healthcare’s launch of VentAssist, GR Healthcare launch of Volume Control Ventilation, and Smith’s Medical launch of Clear-Cluff Pressure Infusor.

Critical and Chronic Care Products Market report is segmented as below

A. Critical and Chronic Care Products – Market By Treatment

1. Surgical
2. Medical
3. Pediatric
4. Psychiatric
5. Intermediate
6. Burn care
7. Trauma care
8. Myocardial infarction
I. Pulmonary
II. Heart transplant
III. Intermediate CCU
IV. Other coronary care
V. Other intensive care treatment

B. Critical and Chronic Care Products – Market By Devices

1. Anesthesia Airway

I. Endotracheal Tubes
II. Intubation Accessories
III. Mechanical Ventilation

2. Drainage Systems

I. Chest Drainage Catheters
II. External Ventricular Drainage Catheters
III. Thoracic Kits
IV. Wound Drainage System

3. Infusion Systems

I. I.V. Disposables
II. Syringe Infusion Pump Software
III. Syringe Infusion Pump Systems
IV. Large Volume I.V. Administration Sets
V. Volumetric Pump Accessories

4. Patient Monitoring

I. Respiratory Monitors
II. Haemodynamic Monitors
III. Neuro Monitors
IV. Cardiac Monitors
V. Fetal and Neonatal Monitors
VI. Multi-Parameter Monitors

5. Pressure Monitoring

I. Pressure Infusors
II. Pressure Monitoring Accessories and Components
III. Pressure Transducer Systems

6. Ventilators

1. Non Invasive ventilators
I. Volume-cycled ventilators
II. Pressure-cycled ventilators
III. Flow-cycled ventilators
IV. Time-cycled ventilators
V. Manual Ventilation
VI. Mechanical Ventilation
VII. Invasive ventilators

C. Critical and Chronic Care Products – Market Temperature Management

1. Blood & Fluid Warming Systems
2. Convective Warming Systems
3. Hyperthermia and Hypothermia Management Devices

D. Critical and Chronic Care Products – Market Vascular Access

1. Implantable Ports
2. Peripheral lntra Venous Catheters

E. Critical and Chronic Care Products – Market By patient care

1. Level 0 – normal wound care
2. Level 1 – patients with deteriorating conditions who need additional care
3. Level 2 – patients with single failing organ system or post- operative care
4. Level 3 – patients requiring additional advanced support systems

F. Critical and Chronic Care Products – Market Blood Testing devices

1. Blood Glucose Meter
I. Test Strips
II. Lancing Devices
G. Critical and Chronic Care Products – Market By end users

1. Hospitals
2. Ambulatory Surgical Centres/Clinics
3. Rehabilitation centres

H. Critical and Chronic Care Products Marketby Geography (covers 10+ countries)
I. Critical and Chronic Care Products Market
J. Manufacturer Citied / Interviewed

1. Amy's Kitchen, Inc
2. Conagra Brands, Inc.
3. The Kraft Heinz Company
4. Dr. Oetker
5. Konspol Group
6. Stefano Foods
7. A/S Crispy Food International
8. Geia Food
9. Kellydeli
10. Seachill
11. Isidro 1952
12. Nomad Foods Ltd.
13. Larsen Danish Seafood Gmbh
14. Homann Feinkost Gmbh
15. Marine Harvest Asa
16. Clama Gmbh & Co. Kg
17. Greencore Group Plc
18. Sodebo
19. Natsu Foods
20. Company 20
21. Company 21
22. Company 22

Related Report:
A. Care Management Solutions
https://industryarc.com/Report/15664/care-management-solutions-market.html

B. Biosimilars Market
https://industryarc.com/Report/10593/biosimilars-market.html

What can you expect from the report?

The Critical and Chronic Care Products MarketReport is Prepared with the Main Agenda to Cover the following 20 points:

1. Market Size by Product Categories & Application 11. Demand Analysis (Revenue & Volume)
2. Market trends & Relevant Market Data 12. Country level Analysis
3. Manufacturer Landscape 13. Competitor Analysis
4. Distributor Landscape 14. Market Shares Analysis
5. Pricing Analysis 15. Value Chain Analysis
6. Top 10 End user Analysis 16. Supply Chain Analysis
7. Product Benchmarking 17. Strategic Analysis
8. Product Developments 18. Current & Future Market Landscape Analysis
9. Mergers & Acquisition Analysis 19. Opportunity Analysis
10. Patent Analysis 20. Revenue and Volume Analysis

Frequently Asked Questions:

Q. Does IndustryARC publish country or application based reports in Critical and Chronic Care Products Market segment?
Response: Yes, we do have separate reports as mentioned below:

1. America Critical and Chronic Care Products Market (2018-2023)
2. Europe Data Critical and Chronic Care Products Market (2018-2023)
3. Asia-Pacific Critical and Chronic Care Products Market (2018-2023)
4. Treatment Critical and Chronic Care Products Market (2018-2023)
5. Devices Critical and Chronic Care Products Market (2018-2023)
6. Temperature Management Critical and Chronic Care Products Market (2018-2023)
7. Vascular Access Critical and Chronic Care Products Market (2018-2023)
8. Patient Care Critical and Chronic Care Products Market (2018-2023)
9. Blood Testing Devices Critical and Chronic Care Products Market (2018-2023)
10. End User Critical and Chronic Care Products Market (2018-2023)

Q. Does IndustryARC provide customized reports and charge additionally for limited customization?
Response: Yes, we can customize the report by extracting data from our database of reports and annual subscription databases. We can provide the following free customization:

1. Increase the level of data in application or end user industry.
2. Increase the number of countries in geography chapter.
3. Find out market shares for other smaller companies or companies which are of interest to you.
4. Company profiles can be requested based on your interests.
5. Patent analysis, pricing, product analysis, product benchmarking, value and supply chain analysis can be requested for a country or end use segment.

Any other custom requirements can be discussed with our team, drop an e-mail to sales@industryarc.com to discuss more about our consulting services.

To request for a proposal, provide your details in the below link:
https://industryarc.com/subscription.php

Media Contact:

Mr. Venkat Reddy
Sales Manager
Email: venkat@industryarc.com
Contact Sales: +1-614-588-8538 (Ext-101)

About IndustryARC:

IndustryARC is a Research and Consulting Firm that publishes more than 500 reports annually, in various industries such as Agriculture, Automotive, Automation & Instrumentation, Chemicals and Materials, Energy and Power, Electronics, Food & Beverages, Information Technology, Life sciences &Healthcare.

IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications in a Market. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business.

We look forward to support the client to be able to better address their customer needs, stay ahead in the market, become the top competitor and get real-time recommendations on business strategies and deals. Contact us to find out how we can help you today.

Venkat Reddy
IndustryARC
+1-614-588-8538
email us here


Source: EIN Presswire